BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BC Week In Review | Feb 2, 2018
Company News

Seattle Genetics buying Cascadian for $614M

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
BC Extra | Jan 31, 2018
Company News

Seattle Genetics buying Cascadian for $614M, raising cash

Seattle Genetics Inc. (NASDAQ:SGEN) said it will acquire cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) for $10 per share in cash, or about $614 million. The price is a 69% premium to Cascadian's close of $5.90...
Items per page:
1 - 4 of 4